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ABSTRACT
Objective: Tocotrienol is a natural Vitamin E compound with greater antioxidant activity than tocopherol. However, tocotrienol is considered unstable, 
which limits its handling and use in various product formulations. In this study, to enhance the stability of tocotrienol, tocotrienol oil was converted 
into a powder through a microencapsulation method using ethylcellulose (EC) as the coating material.
Methods: Tocotrienol microcapsules were formulated with EC in ratios of 1:2 and 1:3 by solvent evaporation (SE) and spray drying techniques. 
The obtained microcapsules were then characterized in terms of shape and morphology, particle size, entrapment efficiency, percentage yield, 
flow properties, water content, swelling, and drug release. In addition, stability studies at both room temperature and elevated temperatures were 
performed.
Results: Our results demonstrated that the tocotrienol microcapsules were of a white-yellowish powder of irregular shape, with particle sizes between 
1 μm and 60 μm and entrapment efficiency of 21.60% and 99.75%. After 12 weeks of storage at room temperature, the remaining level of tocotrienol 
in the microcapsules was 96.46–97.74%. In the accelerated stability study at elevated temperatures, the resulting k25 values ranged from 1.02×10-5 to 
1.32×10-5/h. Thus, the predicted shelf-life (t90) of the microencapsulated tocotrienol was determined to be between 11.01 and 14.27 months.
Conclusion: The microencapsulation of tocotrienol with EC using SE and spray drying techniques produced a solid form of tocotrienol that was 
considerably more stable than the natural form of tocotrienol.
Keywords: Microencapsulation, Solvent evaporation, Spray drying, Stability test, Tocotrienol.
INTRODUCTION
Tocotrienol, a member of the Vitamin E family, is a vitamin component 
in oil form present in high amounts in rice bran, palm, and annatto 
seeds [1]. Tocotrienol is known to have greater antioxidant activity than 
tocopherol. Indeed, in rat liver microsomes, α-tocotrienol was shown 
to provide 40 times greater protection against Fe (II) 1 nicotinamide 
adenine dinucleotide phosphate-induced lipid peroxidation than 
α-tocopherol. Alpha-tocotrienol has also been shown to be 6.5 
times more effective in protecting CYP-450 enzymes from oxidative 
damage [2]. However, tocotrienol is considerably more unstable 
compared with tocopherol. One reason for this is that tocotrienol 
in its natural oil form has three trans double bonds in its side chain, 
which makes it easily oxidized. In addition, compared with tocopherol, 
tocotrienol oil is more sensitive to exposure to high heat [3]. As such, 
the study and use of tocotrienol itself remain rare. Therefore, to use 
tocotrienol in product formulations, it is necessary to convert it into 
a stable nutraceutical product. One method that has been used with 
other compounds is microencapsulation, which can convert a liquid 
into a solid form. As a technique, microencapsulation is the process of 
applying a thin coating to small particles of solids or droplets of liquid 
and dispersions [4].
In this study, tocotrienol oil was microencapsulated through solvent 
evaporation (SE) and spray dry (SD) techniques using ethylcellulose 
(EC) coating. The produced microcapsules were characterized and 
tested for stability with tocotrienol oil as a comparison. In addition, the 
microcapsules were characterized in terms of shape and morphology, 
percentage yield, entrapment efficiency, water content, particle size 
distribution, swelling, flow properties, and drug release. Stability 
testing was performed to evaluate the physical and chemical stability 
at both room temperature and elevated temperatures, and the shelf 
life was determined. Collectively, our findings indicate that the 
microencapsulation of tocotrienol should facilitate its handling and 
stability in product formulations.
METHODS
Materials
Tocotrienol was purchased from Davos Life Science (Singapore), EC N-10 
was purchased from Aqualon (USA), sodium lauryl sulfate (SLS), Span 
80, Tween 80, liquid paraffin, acetone, ethanol 96%, dichloromethane, 
and distilled water were purchased from PT. Brataco (Indonesia).
Preparation of tocotrienol microcapsules
The tocotrienol microcapsules were prepared through emulsion SE 
(ESE), SE, and SD techniques into eight formulas, as shown in Table 1.
ESE method
Solution A was prepared from dissolved EC and tocotrienol (T3) in 
acetone. Solution B was prepared from Span 80 (1.5%) in liquid paraffin 
(light). Solution A was added into Solution B with a stirring speed of 
1500 rpm for 2 h at 60°C. Microcapsules were then filtered, washed 
with SLS solution (7.5%) and distilled water, and dried [5].
SE method
Solution A was prepared by dissolving EC and T3 in a mixture of 
ethanol and dichloromethane (1:1). Solution B was prepared by 
dissolving Tween 80 (0.1%) in distilled water. Solution A was poured 
into Solution B, then stirred at a speed of 2000 rpm for 1 h at room 
temperature. The microcapsules were collected by filtering and then 
dried [6].
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SD method
Microcapsules were prepared with two types of solvents:
a. EC and T3 were dissolved in acetone at a drug/polymer ratio of 1:2 
and 1:3
b. EC and T3 were dissolved in a mixture of acetone:ethanol (1:2) at a 
drug/polymer ratio of 1:2 and 1:3 [7]
Each solution was sprayed through a mini spray drier B290 (Buchi, 
Swiss) under the conditions shown in Table 2.
Characterization of microcapsules
Shape and morphology
Scanning electron microscopy (SEM) (FEI FE-SEM Inspect F50, USA) 
was used to characterize the surface topography of the microcapsules 
coated with a gold layer at magnifications of 500, 1000, 3000, and 5000 
times [8].
Percentage yield
The weight of the microcapsules obtained was compared with the total 
weight of both the drug and polymer used [8,9].
Entrapment efficiency
An amount of the microcapsules equivalent to 10 mg of T3 was dissolved 
in a 100-mL volumetric flask using 96% ethanol. The absorbance was 
measured at the λ maximum of T3 [8,9].
Water content
One gram of the microcapsules was measured using a moisture analyzer 
at 105°C [8].
Particle size distributions
The microcapsules were dispersed in distilled water then observed 
with a particle size analyzer (Beckman Coulter, Germany). The particle 
size distribution curve was based on the particle volume.
Table 1: Formulation of tocotrienol microcapsules
Ingredients Formula
ESE SE SD
F1 F2 F3 F4 F5 F6 F7 F8
T3 (gr) 0.5 0.5 0.5 0.5 2.5 2.5 2.5 2.5
EC (gr) 1 1.5 1 1.5 5 7.5 5 7.5
Acetone (mL) 20 30 - - 100 150 - -
Liquid paraffin 
(mL)
60 90 - - - - - -
Span 80 (mL) 0.9 1.35 - - - - - -
Dichloromethane: 
ethanol (1:1) (mL)
- - 20 30 - - - -
Distilled  
water (mL)
- - 100 150 - - - -
Tween 80 (mL) - - 0.1 0.15 - - - -
Acetone:ethanol 
(1:2) (mL)
- - - - - - 100 150
Drug-polymer 
ratio
1:2 1:3 1:2 1:3 1:2 1:3 1:2 1:3
ESE: Emulsion solvent evaporation, SE: Solvent evaporation, SD: Spray dry
Microcapsule flow properties
The compressibility index of the microcapsules was tested with a 
bulk-tapped density tester. The microcapsule volume after tapping 300 
times was measured. The flow rate was calculated using a flow meter. The 
repose angle was measured from the steepest angle of the microcapsules.
Swelling test
The microcapsules (100 mg) were added to 10 mL of medium (distilled 
water and phosphate buffer pH 6.8) in a centrifuge tube and immersed 
for 60 and 120 min. After centrifugation (4000 rpm), the supernatant 
was removed, and the final weight was determined [10].
Drug release study
The microcapsules release profile was evaluated in 100 mL phosphate 
buffer medium pH 6.8 added to 100 mg SLS (0.1%) to help the T3 
dissolve. T3 release was carried out at 37±0.5°C with an agitation speed 
of 100 rpm for 8 h. Five milliliters aliquots of the samples were taken 
at 5, 15, 30, 45, 60, 90, 120, 180, 240, 300, 360, 420, and 480 min. The 
percentage of released T3 was calculated. T3 levels were determined by 
spectrophotometry at the λ maximum [10].
Stability study
Room temperature stability study
The stability of the microcapsules F1–F8 was compared with T3 oil at 
room temperature (±25°C) for 12 weeks. Organoleptic observation and 
T3 level determination using a spectrophotometer were performed on 
each sample every week.
Accelerated stability study
The microcapsules F1–F8 were compared with T3 oil to observe 
stability and shelf life. The samples were placed in vial bottles and 
tested at 80, 90, and 100°C. At each temperature, sample aliquots were 





Through microencapsulation, T3 was successfully converted from an 
oil into a powder form with EC by the ESE, SE, and SD methods. The 
SEM examination was performed on four types of microcapsules to be 
representative of each method and to observe its surface morphology. 
Table 2: Optimum spraying conditions





Acetone 80 70 5 3
Acetone:ethanol (1:2) 90 80 5 3
Fig. 1: Microphotographs of the tocotrienol microcapsules (a) F2, 
(b) F4, (c) F6, and (d) F8 at a 500×
ba
c d
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Test results are shown in Fig. 1. The shape of the microcapsules was not 
spherical but rather varied due to the different methods of manufacture. 
The shape produced by the ESE and SE methods appeared to depend 
on the droplet and stirring speeds. The F8 formulation, which was 
produced through the SD method with acetone: ethanol (1:2), was not 
spherical; however, the F6 formulation prepared with acetone as the 
solvent was round and spherical. The surface morphology of all the 
microcapsules appeared porous; this factor can affect T3 release.
Percentage yield
The test results are shown in Table 3. The percentage yield value showed 
good results, ranging from 62.46 to 87.23%. The percentage yield value of 
the microcapsules produced by the ESE method was lower because a lot 
of T3 was not trapped. The percentage yield value of the microcapsules 
produced by the SD method was generally quite good considering a lot 
of the material was lost during the drying process. This can be explained 
by the EC coating ability and optimal inlet/outlet temperature settings.
Entrapment efficiency
The results are shown in Table 3, with entrapment efficiency 
ranging from 21.60 to 99.75%. The lowest value was obtained from 
microcapsules in the F1 and F2 formulations, at 21.60% and 27.48%, 
respectively, while the six other formulas demonstrated high values in 
the range of 91.06%–99.75%. The low entrapment efficiency values of 
F1 and F2 were likely caused by the ESE method, which is considered 
less suitable for oil materials. The T3 oil has properties as such that 
it can be mixed with other oils, such as paraffin oil. It has also been 
described that drug loss into the continuous phase occurs while the 
dispersed phase stays in a transitional, semi-solid state. If a drug is 
more soluble in the continuous phase than in the dispersed phase, 
it will easily diffuse into the continuous phase during this stage [8]. 
Entrapment efficiency values were higher for microcapsules with 
a higher coating concentration. The entrapment efficiency of other 
microcapsules showed high values, indicating the suitability of the SE 
and SD methods.
Table 3: Percentage yield, entrapment efficiency, water content, and particle size value of microcapsules F1–F8
Microcapsule formulation Percentage yield (%) Entrapment efficiency (%) Water content (%) Particle size (µm)
Mean Median
F1 65.36 21.60±1.95 4.71±0.42 15.49 14.44
F2 70.11 27.48±1.81 6.36±0.13 16.30 14.78
F3 82.38 99.30±0.62 4.63±0.33 19.96 21.15
F4 87.23 99.67±1.69 4.46±0.53 20.80 23.11
F5 74.74 91.06±0.73 3.65±0.07 22.04 24.54
F6 86.35 99.25±0.14 3.97±0.06 24.17 25.99
F7 62.46 99.15±0.82 4.06±0.04 21.93 25.02
F8 75.20 99.75±0.12 5.55±0.05 29.59 30.93
Fig. 2: Particle size distribution of microcapsules F1-F8
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Particle size distribution
The microcapsules particle size distribution chart in Fig. 2 demonstrates 
that the microcapsules sizes ranged from 1 μm to 60 μm. Test results 
listed in Table 3 showed that the particle size of the microcapsules 
F1–F8 had value ranges for the mean and median from 14.44 μm to 
30.93 μm and 15.49 μm to 29.59 μm, respectively. McNamee et al. [11] 
reported that microcapsule sizes produced by the SD method are 
affected by solution viscosity, feed flow, and nozzle size [12]. The size 
of the microcapsules produced by the SE and ESE methods decreased 
with increasing stirring time. Indeed, it has been reported that the 
particles get smaller, while the particle distribution becomes narrower, 
with increasing stirring rates and times because the particles become 
separated in a stable form without aggregation [13].
Water content
The test results are shown in Table 3. Based on the test, all formulas 
of the microcapsules had a relatively low water content, which ranged 
between 3.65% and 6.36%. The water in the microcapsules is believed 
to be derived from the distilled water during their preparation. EC 
is stable and not affected by water so the microcapsules are not 
considered hygroscopic.
Microcapsules flow properties
In general, all microcapsules indicated poor flow properties. Among the 
F1–F8 formulations, the best flow properties were demonstrated by F5 
and F7. Flow properties can be determined through the angle of repose, 
the compressibility index, and the Hausner ratio. Microcapsules in the 
F1 and F2 formulations could not flow. The F5 and F7 formulations 
showed very good flow properties with an angle of repose <30°, while 
the F3, F4, F6, and F8 formulations were considered good with an angle 
of repose between 31 and 35°. However, based on the compressibility 
index and Hausner ratio values, only the F7 and F5 formulations 
were considered good, while the other formulas did not meet the 
requirements of good flow properties.
Swelling test
The microcapsule swelling index ranged from 76.27% to 318.06% in 
distilled water, while that in phosphate-buffered ranged from 126.02% 
to 340.62%. The low swelling index values can be explained by the EC 
coating with hydrophobic properties. As such, the microcapsules with 
a higher coating concentration showed higher swelling index values. 
Particle size also affects the swelling index, with the F1 and F2 formulas 
having a smaller size compared with the other formulas.
Release study
The dissolution profiles of the microcapsules in the F1–F8 formulations 
are shown in Fig. 3. T3 was released from all microcapsules produced by 
the SD method, with the fastest release by F7 at 3 h, followed by F5 at 3.5 
h, F8 at 5 h, and F6 at 6.5 h. F3 and F4 produced by the SE method could 
only release all the T3 after 5 and 8 h, respectively. This is in contrast to 
the F1 and F2 formulations, which only was able to release T3 at 67.61% 
and 54.46%, respectively, after testing for 8 h. After 3.5 h, F7 and F5 
released all the T3, while F6 and F8 only released T3 as much as 79.93% 
and 60.09%, respectively. Slower release from F6 to F8 was likely due 
to the larger particle sizes. In general, microcapsules produced by the 
SD method showed a faster release than other methods due to the small 
and uniform particle size. F3 and F4 produced by the SE method could 
only release all the T3 after 5 and 8 h, respectively. The release of F3 was 
faster due to the decreased coating concentration compared with F4. 
F1 and F2 produced by the ESE method showed the slowest dissolution 
rate among the formulas. For F1 and F2, the decreased release of T3 
was likely influenced by the low number of T3 molecules trapped in 
the microcapsules. In addition, despite the particle size being not much 
different from the other formulas, the reduced T3 content in F1 and F2 
resulted in a greater coating concentration; thus diffusion was slower. 
Furthermore, microcapsules with different coating concentrations 
are known to have different wall thicknesses, with those of smaller 
particle size having thinner walls. For EC as a water-insoluble polymer, 
drug release is mainly driven by permeation through the hydrophobic 
membrane within water-filled pores [14].
Stability study
Stability study at room temperature
Changes in T3 levels in the microcapsule F1–F8 formulations and T3 
oil are shown in Fig. 4. T3 levels in the microcapsules and those of the 
non-encapsulated T3 after 12 weeks storage at room temperature 
decreased, with remaining T3 levels at 95.04% for the oil form and 
97.74% to 96.46% for the F1–F8 microcapsule formulations. Stability 
from the lowest to the highest T3 remaining concentration was: T3 oil 
>F1 >F2 >F3 >F7 >F5 >F8 >F6 >F4.
F1 and F2 formulations produced by the ESE method showed the 
lowest stability among the formulas. F3–T3 levels also decreased 
significantly compared with the F4 formulations due to a decreased 
coating concentration. F4–F8 formulations produced by the SD method 
showed good chemical stability.
The content of T3 oil at room temperature decreased by 4.96% more 
than the microcapsule F1–F8 formulations. This value indicated that T3 
Fig. 3: Drug release profiles of the tocotrienol microcapsules 
F1–F8 in phosphate buffer (pH 6.8)
Fig. 4: Stability study of the tocotrienol microcapsule F1–F8 
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in oil form degraded faster than its solid form, which is consistent with 
the presence of the double bonds which are easily oxidized.
Stability in solid form can be affected by humidity, temperature, 
excipients, oxygen, and light. Moisture can also affect stability if the 
active substance is water-soluble and a hygroscopic excipient is used. 
Due to the humidity, a hydrolysis reaction can occur and increase the 
degradation rate of the active substance [15].
Accelerated stability study
The study was conducted at three different temperatures to determine 
the T3 degradation rate of the microcapsules F1–F8. The temperature 
selection was optimized at 80, 90, and 100°C, which can result in 
decreased levels of T3 so that the rate constant can be calculated.
The results are shown in Table 4 and shown that the k25, t90, t1/2, and Ea 
values varied. The k25 values of the F1–F8 microcapsules were ranged 
from 1.02×10-5 to 1.32×10-5/h, while that of the T3 oil was 2.02×10-5/h. 
The degradation rate at 25°C from the lowest to the highest was: F8 >F6 
>F4 >F5 >F7 >F2 >F1 >F3 >T3 oil.
Common degradation reactions include hydrolysis and oxidation 
reactions. In a solid form such as microcapsules, oxidation can occur 
from hydrolysis in the solid-state only when the active substance is 
water-soluble. Oxidative degradation can occur spontaneously under 
oxygen influence without a catalyst. This reaction occurs in unsaturated 
oils such as T3 [16]. As researched by Simonne and Eitenmiller [17], 
T3 degrades rapidly in oil form due to the saturated fatty acid content. 
This happens when the polyunsaturated fatty acids content in an oil is 
low such that the T3 becomes the main substrate that reacts with the 
oxygen [3]. The shelf life and half-life values of the microcapsule F1–F8 
formulations and the T3 oil followed the reverse order of the k25 value, 
with the lowest to highest being T3 oil >F3 >F1 >F2 >F7 >F5 >F4 >F6 
>F8. The F1–F8 shelf life value ranged from 11.01 to 14.27 months with 
a half-life value of 6.06 to 7.85 years, while those of the T3 oil were 7.30 
months and 4.02 years, respectively.
CONCLUSION
Based on this study, it can be concluded that T3 oil can be converted to 
a solid form using EC coating in conjunction with SD and SE methods. 
The characteristic microcapsules were a yellowish powder, with a 
particle size of 1–60 μm and entrapment efficiency of 21.60%–99.75%; 
the best results were obtained from microcapsules produced by the 
SD method. In addition, it can be concluded that the T3 microcapsules 
Table 4: k25, t90, t1/2, and Ea values of microcapsules F1–F8 and 
T3 oil
Formula k25×10-5 (h-1) t90 (months) t1/2 (years) Ea (kcal/mol)
F1 1.31±0.03 11.14±0.24 6.30±0.13 18.42±0.27
F2 1.18±0.06 12.41±0.65 6.83±0.36 18.75±0.28
F3 1.32±0.03 11.01±0.28 6.06±0.16 21.00±0.14
F4 1.08±0.06 13.49±0.77 7.42±0.42 20.07±0.17
F5 1.09±0.04 13.38±0.52 7.36±0.29 20.08±0.19
F6 1.04±0.05 14.06±0.76 7.73±0.42 19.19±0.26
F7 1.15±0.02 12.73±0.24 7.00±0.13 19.86±0.02
F8 1.02±0.01 14.27±0.20 7.85±0.11 19.53±0.01
T3 oil 2.02±0.28 7.30±0.96 4.02±0.53 19.27±0.39
showed better stability than the T3 oil, particularly for the F6 and F8 
formulations. After 12 weeks of storage at room temperature, T3 levels 
in the microcapsules ranged from 96.46% to 97.74%. The shelf life value 
of the microcapsule F1–F8 formulations was 11.01–14.27 months.
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